BR112022010278A2 - Terapia combinada que envolve compostos macrocíclicos de diarila - Google Patents

Terapia combinada que envolve compostos macrocíclicos de diarila

Info

Publication number
BR112022010278A2
BR112022010278A2 BR112022010278A BR112022010278A BR112022010278A2 BR 112022010278 A2 BR112022010278 A2 BR 112022010278A2 BR 112022010278 A BR112022010278 A BR 112022010278A BR 112022010278 A BR112022010278 A BR 112022010278A BR 112022010278 A2 BR112022010278 A2 BR 112022010278A2
Authority
BR
Brazil
Prior art keywords
diaril
macrocyclic
compounds
combined therapy
therapy involving
Prior art date
Application number
BR112022010278A
Other languages
English (en)
Inventor
Deng Wei
Zhai Dayong
Rodon Laura
W Murray Brion
J Cui Jingrong
Original Assignee
Turning Point Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Turning Point Therapeutics Inc filed Critical Turning Point Therapeutics Inc
Publication of BR112022010278A2 publication Critical patent/BR112022010278A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

TERAPIA COMBINADA QUE ENVOLVE COMPOSTOS MACROCÍCLICOS DE DIARILA. A presente revelação está relacionada aos métodos e às composições para o tratamento de câncer com um macrociclo de diarila em combinação com um inibidor de KRAS, por exemplo, um inibidor de KRAS G12C.
BR112022010278A 2019-11-27 2020-11-25 Terapia combinada que envolve compostos macrocíclicos de diarila BR112022010278A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962941026P 2019-11-27 2019-11-27
US202062981822P 2020-02-26 2020-02-26
US202063005681P 2020-04-06 2020-04-06
PCT/US2020/062390 WO2021108682A1 (en) 2019-11-27 2020-11-25 Combination therapy involving diaryl macrocyclic compounds

Publications (1)

Publication Number Publication Date
BR112022010278A2 true BR112022010278A2 (pt) 2022-10-04

Family

ID=76129920

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022010278A BR112022010278A2 (pt) 2019-11-27 2020-11-25 Terapia combinada que envolve compostos macrocíclicos de diarila

Country Status (12)

Country Link
US (2) US11654145B2 (pt)
EP (1) EP4065125A4 (pt)
JP (1) JP2023505056A (pt)
KR (1) KR20220133866A (pt)
CN (1) CN114901286B (pt)
AU (1) AU2020391222A1 (pt)
BR (1) BR112022010278A2 (pt)
CA (1) CA3162632A1 (pt)
IL (1) IL293206A (pt)
MX (1) MX2022006500A (pt)
TW (1) TW202133855A (pt)
WO (1) WO2021108682A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3168648A1 (en) * 2020-01-31 2021-08-05 Verastem, Inc. Combination therapy for treating abnormal cell growth
BR112023018734A2 (pt) * 2021-03-17 2023-10-24 Amgen Inc Regimes de dosagem de sotorasib

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102713606A (zh) * 2009-11-13 2012-10-03 无限制药股份有限公司 用于鉴定、评估、预防和治疗癌症的组合物、试剂盒和方法
UA121206C2 (uk) * 2014-01-24 2020-04-27 Турнінґ Поінт Терапьютикс, Інк. Діарильні макроцикли як модулятори протеїнкіназ
JO3556B1 (ar) * 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
CN107735399B (zh) 2015-07-02 2021-01-26 特普医药公司 作为蛋白质激酶的调节剂的手性二芳基大环
CN113354653A (zh) 2015-07-06 2021-09-07 特普医药公司 二芳基大环多晶型物及其制备方法
AU2016344058A1 (en) * 2015-10-26 2018-05-17 Array Biopharma Inc. Point mutations in Trk inhibitor-resistant cancer and methods relating to the same
TWI808958B (zh) * 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
US20190134056A1 (en) * 2017-03-10 2019-05-09 The Trustees Of The Stevens Institute Of Technolog K-ras mutations and antagonists
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
US10647715B2 (en) 2017-11-15 2020-05-12 Mirati Therapeutics, Inc. KRas G12C inhibitors
HRP20230377T1 (hr) 2017-11-15 2023-06-23 Mirati Therapeutics, Inc. Inhibitori mutacije kras g12c
CN111971286B (zh) * 2018-01-18 2023-04-14 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡咯并[2,3-d]嘧啶化合物
JP7546549B2 (ja) * 2018-09-10 2024-09-06 ミラティ セラピューティクス， インコーポレイテッド 組み合わせ療法
CN110256421A (zh) * 2019-06-26 2019-09-20 微境生物医药科技(上海)有限公司 Kras-g12c抑制剂
KR20220134522A (ko) * 2019-11-27 2022-10-05 터닝 포인트 테라퓨틱스, 인크. 디아릴 매크로시클릭 화합물을 수반하는 병용 요법
WO2021148581A1 (en) * 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Also Published As

Publication number Publication date
MX2022006500A (es) 2022-07-04
EP4065125A1 (en) 2022-10-05
US11654145B2 (en) 2023-05-23
TW202133855A (zh) 2021-09-16
AU2020391222A1 (en) 2022-06-30
JP2023505056A (ja) 2023-02-08
EP4065125A4 (en) 2024-01-03
WO2021108682A1 (en) 2021-06-03
CA3162632A1 (en) 2021-06-03
US20240033266A1 (en) 2024-02-01
IL293206A (en) 2022-07-01
CN114901286B (zh) 2024-05-10
US20210220364A1 (en) 2021-07-22
CN114901286A (zh) 2022-08-12
KR20220133866A (ko) 2022-10-05

Similar Documents

Publication Publication Date Title
MX2019008701A (es) Terapia de combinacion que involucra compuestos macrociclicos de diarilo.
CR20190252A (es) Compuestos de 7-feniletilamino-4h-pirimido[4,5-d][1,3]-oxazin-2-ona como inhibidores de idh1 e idh2 mutantes
PH12020551244A1 (en) Pd-1/pd-l1 inhibitors
PH12021500004A1 (en) Pd-1/pd-l1 inhibitors
BR112013000651A2 (pt) combinações de inibidores de cinase para o tratamento de câncer.
BR112018072560A2 (pt) terapia de combinação para tratamento do câncer
BR112022010277A2 (pt) Terapia combinada que envolve compostos macrocíclicos de diarila
NI201000084A (es) Tratamiento de cáncer de ovarios con un compuesto yodonitrobenzamida en combinación con agentes anti-tumorales
BR112022010278A2 (pt) Terapia combinada que envolve compostos macrocíclicos de diarila
MX369609B (es) Una composición para usarse en el tratamiento de cáncer deficiente en nmt2.
BR112015027474A8 (pt) anticorpo, composição, método de tratamento do paciente que sofre de câncer e uso de um anticorpo.
CO2024009571A2 (es) Inhibidores de parp1
NI201900096A (es) Moduladores de la expresión de pcsk9
MX2019003569A (es) Metodos para tratar el cancer con bavituximab en funcion de niveles de b2 glucoproteina 1 y ensayos de estos.
MX2020009147A (es) Moduladores de la expresion de irf4.
CO2022000270A2 (es) Inhibidores de enzimas
BR112019008241A2 (pt) tratamento do prurigo nodular
BR112022008295A2 (pt) Inibição combinada de pd-1, tgfbeta e tigit para o tratamento de câncer
BR112017014914A2 (pt) terapia combinada para hipertensão pulmonar
AR117094A1 (es) Moduladores de expresión irf5
BR112022007787A2 (pt) Inibição combinada de pd-1, tgfss e atm juntamente com radioterapia para o tratamento de câncer
BR112018069174A2 (pt) tratamento de prurido urêmico
MX2021003263A (es) Combinacion de un antagonista de proteina de muerte programada 1 (pd-1), un inhibidor de ataxia telangiectasia y proteina relacionada con rad3 (atr) y un agente de platino para el tratamiento de cancer.
MX2021002818A (es) Métodos para tratar el cáncer mediante la inhibición de la enzima conjugadora de ubiquitina e2 k (ube2k).
BR112022022634A2 (pt) Inibidores de atr para o tratamento de câncer